-
China’s Sciwind Biosciences Partners with HK inno.N for Ecnoglutide Rights in South Korea
•
China’s Sciwind Biosciences Co., Ltd has entered into a licensing and partnership agreement with South Korea’s HK inno.N Corporation (KOSDAQ: 195940) for the development and commercialization of ecnoglutide injection (XW003), a novel glucagon-like peptide-1 (GLP-1) analog, for the treatment of type 2 diabetes, obesity, and metabolic associated severe hyperglycemia (MASH)…
-
Sciwind Biosciences’ Ecnolgutide Shows Promising Phase III Results in Type 2 Diabetes Treatment
•
Sciwind Biosciences Co., Ltd, a China-based pharmaceutical company, has released the latest topline Phase III data for its lead anti-obesity candidate, ecnolgutide (XW003), in the treatment of type 2 diabetes mellitus (T2DM), following positive Phase II results for the drug as an obesity treatment released in June 2023. The randomized,…
